PA GOODDOCTOR (01833) Rises Over 5% Against Market Trend, Selected as Pilot Unit for High-Quality Workplace Health Management

Stock News
2025/12/15

PA GOODDOCTOR (01833) surged more than 5% against the market trend, reaching HK$14.32 with a trading volume of HK$264 million by the time of writing.

The rise follows the announcement that PA GOODDOCTOR Investment Management Co., Ltd. has been selected as one of the first pilot units for high-quality workplace health management. The selection was unveiled during the "Implementing Health Priority Development Strategy and Sharing Health Management Responsibilities" national pilot project on major chronic disease prevention and innovation integration, held in Beijing from December 11-12, 2025.

The company's inclusion is attributed to its extensive experience, professional service capabilities, and comprehensive health management model covering the entire employee health lifecycle. The national project recognized PA GOODDOCTOR for its unique "finance + healthcare" integrated service approach, embodied in its corporate health strategy.

PA GOODDOCTOR's strategy focuses on transforming corporate health management in three key areas: shifting from "post-treatment claims" to "preventive care," moving from "general welfare" to "targeted interventions," and transitioning from a "cost center" to "value creation."

As part of the pilot program in East and South China, PA GOODDOCTOR will leverage its integrated online-offline healthcare network to provide seamless services, including online consultations, specialist appointments, and chronic disease management. The company will also utilize AI and big data to help enterprises build employee health profiles and disease risk prediction models, enabling precise health management.

Additionally, PA GOODDOCTOR will collaborate with pilot companies to explore innovative mechanisms linking health management outcomes with insurance costs, testing the feasibility of optimizing overall welfare investments through health behavior incentives.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10